title: Maintenance therapy in gastro-oesophageal reflux disease.
abstract: Gastro-oesophageal reflux disease (GORD) is a chronic condition. Symptom control and the maintenance of healing of erosive oesophagitis, if present, are important topics. In patients responding to a proton pump inhibitor (PPI) and showing no treatment symptoms it is appropriate to consider long-term treatment strategies, whether continuous, intermittent or on demand. Maintenance PPI therapy is well tolerated for up to 10 years of continuous use. Furthermore, tachyphylaxis does not occur during long-term maintenance PPI therapy. Previous concerns about risks of long-term PPI therapy in Heliobacter pylori-negative or H. pylori-positive patients have not materialized, while no cases of intestinal metaplasia with dysplasia or adenocarcinoma were found. The choice between medical and surgical therapy should depend upon informed patient preference. The optimal candidate for antireflux surgery is a young patient, with typical GORD symptoms, with erosive oesophagitis, with previous complete symptom resolution on acid-suppression therapy and unable to undergo continuous therapy, or alternatively in patients with regurgitation predominating over heartburn as long as the surgical procedures are conducted by an expert surgical team. Endoscopic therapy for erosive GORD should currently be regarded as experimental. The endoscopic procedures are safe, although they remain untested in patients with severe erosive oesophagitis and/or significant hiatal hernia.
authors.affiliation: Department of Medicine, University of Valencia, Spain. miguel.bixquert@uv.es
authors.forename: Miguel
authors.initials: M
authors.lastname: Bixquert
mesh_terms: D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects; D003663:Decision Trees; D004334:Drug Administration Schedule; D004724:Endoscopy; D005764:Gastroesophageal Reflux / Q000517:prevention & control*; D006801:Humans; D054328:Proton Pump Inhibitors; D017741:Survivors
chemical_list: D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors